Huadong Medicine's (SHE:000963) unit, Hangzhou Zhongmei Huadong Pharmaceutical, received the approval from China's National Medical Products Administration for the supplemental application of imported drug, mirvetuximab soravtansine injection, according to a Shenzhen bourse filing on Tuesday.
The drug, which has the trade name Elahere, is used to treat patients with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. Its previously conditionally approved indication is now converted to regular approval.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments